PRESS RELEASE | JANUARY 19, 2023
AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
PRESS RELEASE | DECEMBER 19, 2022
AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo
This article may contain information for uses of our product that are not approved in certain countries or regions.
In the United States, RECELL® is approved for use in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use only) or otherwise prohibited.
AVITA Medical is a regenerative medicine company focused on the development and commercialization of innovative therapies with the power to transform lives. Harnessing the regenerative properties of a patient’s own skin, AVITA Medical’s RECELL® System was approved by the U.S. Food and Drug Administration (FDA) in September 2018.
The RECELL® System is the first new PMA-approved treatment in more than 20 years for acute thermal burn wounds.
We’re elevating the standard of care for the treatment of skin restoration.
We’re exploring the potential of this novel technology platform to harness the regenerative properties of a patient’s own skin across a number of dermatological indications.
At AVITA Medical, patients are at the center of what we do. They guide and inspire our tireless dedication to advance bold innovation in regenerative medicine to deliver medical outcomes that transform lives.